ASH 2018 | The definitive guide to multiple myeloma at ASH 2018: part IV
CAR-T and BiTEs take the stage in MM at ASH 2018
The field of immunotherapy in multiple myeloma (MM) continues to grow in leaps and bounds. The American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, has been an excellent opportunity for the latest immunotherapy advancements to be presented and discussed. Here, MM experts Mohamad Mohty, MD, PhD, from the University Pierre & Marie Curie, Paris, France, and Saad Usmani, MD, FACP, of the University of North Carolina School of Medicine, Chapel Hill, NC, dive into the exciting developments including CAR-T and monoclonal antibodies. BCMA continues to be a favored target for CAR-T with no fewer than six constructs under investigation. Bi-specific antibodies are yet another area of great potential under the spotlight in this chat, with AMG 420 offering an “off-the-shelf” option.
